feed,title,long_url,short_url
Benzinga,DupixentÂ® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis,https://www.benzinga.com/pressreleases/20/11/g18567559/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-biologic-medicine-for-childre,https://j.mp/36kCNCf
Benzinga,EIB supports AB Science in its COVID-19 development programme,https://www.benzinga.com/pressreleases/20/11/g18567550/eib-supports-ab-science-in-its-covid-19-development-programme,https://j.mp/36jShGi
